Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

NasdaqGM:KYMR 1 Year Share Price vs Fair Value Explore Kymera Therapeutics's Fair Values from the Community and ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Kymera Therapeutics has introduced KT-579, a first-in-class oral degrader targeting IRF5, which may provide a transformative treatment option for various autoimmune diseases.

According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (NASDAQ: KYMR) notched an almost 23% share price gain across this week. That made it a standout in the ever ...

Woods says the Kymera can run continuously for over two hours on less than a quart of 92 octane+ plus fuel, which is its current fuel capacity. "I would argue its the most fun you can have for a ...

Kymera Press, you see, is owned by Smith and all of the writers and artists are women. Kymera Press started with one title, a comic book based on a TV pilot that Smith wrote years before.